Jonathan D. Campbell, PhD

This commentary explains why comparing a launch price with a value-based price from a cost-effectiveness analysis requires further examination.

This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.

We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.

Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.